Clinical Trial Detail

NCT ID NCT04331067
Title Cabiralizumab in Combination With Nivolumab and Neoadjuvant Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Recruitment Not yet recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Washington University School of Medicine
Indications

triple-receptor negative breast cancer

Therapies

Cabiralizumab + Carboplatin + Nivolumab + Paclitaxel

Carboplatin + Nivolumab + Paclitaxel

Age Groups: adult senior

No variant requirements are available.